Skip to main content

Radioimmunotherapy of carcinoma of colon with [131I]- labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract Aim:

To study the distribution of [131I]-labeled anti-CEA MoAbs and its therapeutic effect on the human colonic cancer model in nude mice. Methods:

A nude mice model of human colonic cancer was established. [131I]-labeled anti-CEA MoAbs were injected intravenously into mice. The distribution of the MoAbs was then determined and the effect of RIT on human colonic cancer was observed. Results:

The [131I]-labeled anti-CEA MoAbs had a specific distribution after injection. Tumor/ non-tumor ratios for [131I]-labeled anti-CEA MoAbs were 10–20 times higher than [131I]-labeled IgG 96 h after injection. Thirty days after injection, significant inhibition of the volume and weight of tumor was observed in the treated mice compared with the control. The tumor growth inhibition rate of 3.1 mCi/kg CEA MoAbs group (LS180, LS174T, SW1116) was 47.8%–64.0%. This was 69.6%–78.6% in the 6.25 mCi/kg CEA MoAbs group, and 81.8%–86.2% in the 12.5 mCi/kg [131I]- labeled anti-CEA MoAbs group. The plasma CEA level was also lower in treated mice. Conclusion:

The results indicate that [131I]-labeled anti-CEA MoAbs can be effective in RIT on colonic cancers.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: colonic cancer; humanized chimeric recombinant monoclonal antibody; nude mice; radioimmunotherapy

Document Type: Research Article

Affiliations: Institute of Radiation Medicine, Beijing 100850, China

Publication date: 2005-10-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more